Winn-Dixie announces intradermal flu vaccine availability at pharmacies
JACKSONVILLE, Fla. — Winn-Dixie has expanded its flu shot options by offering the Fluzone Intradermal vaccination at its in-store pharmacies.
The intradermal vaccine is available for guests at the discounted rate of $29.99 when purchased using their Winn-Dixie customer reward card, the supermarket chain said. The vaccination, which is administered just below the skin with a microneedle that is 90% smaller than regular needles, is approved for customers ages 18 to 64 years. Winn-Dixie said the flu shot option is in addition to the regular flu shot, approved for people ages 3 years and older, and a high-dose flu shot, approved and recommended for people ages 65 years and older, that it offers to customers.
Certain age restrictions may apply in some states regarding pharmacist administration of vaccinations, Winn-Dixie noted.
“We are constantly looking for ways to meet and exceed our guests’ expectations and offering a variety of administrations for the seasonal flu vaccine is just another way for us to properly serve our guests,” Winn-Dixie VP pharmacy John Fegan said. “Our guests’ health and wellness is our primary concern, and being at the forefront with new innovations helps us to provide these services to our neighborhoods.”
Heather Bresch promoted to CEO at Mylan
PITTSBURGH — Generic drug maker Mylan’s board of directors has approved a new management structure for the company, effective Jan. 1, 2012.
Mylan’s board approved the transition of current chairman and CEO Robert Coury to the new role of executive board chairman. With this, Mylan president Heather Bresch will become CEO and directly report to the company’s board.
Replacing Bresch as president is Mylan COO Rajiv Malik, while the generic drug maker’s current president of North America operations, Harry "Hal" Korman, will be promoted to COO. Replacing Korman will be Tony Mauro. Mauro, who serves as president of Mylan Pharmaceuticals, will retain his current role in addition to his new role as president of North America operations.
Coury, Bresch, Malik, Korman and Mauro have agreed to new, 3-year contracts in conjunction with these leadership changes, Mylan said.
EPS rises 22% for Express Scripts in Q3
ST. LOUIS — Pharmacy benefit manager Express Scripts reported its third-quarter results for the period ended Sept. 30.
ESI said that its revenue grew from about $11.3 billion in the third quarter 2010 to nearly $11.6 billion. The company also reported that adjusted earnings per diluted share was 79 cents, representing a 22% increase over last year. Additionally, net income from continuing operations were $324.7 million, compared with $301.5 million in the year-ago period.
In line with the release of its third-quarter results, the company reaffirmed its 2011 guidance, noting that it expects 2011 adjusted earnings per share in a range of $2.95 to $3.05. ESI said it would provide 2012 guidance after the closing of its transaction with fellow PBM Medco.
“Our third-quarter results reflect the continued execution of our business model and the value of fully aligning with clients,” ESI chairman and CEO George Paz said. “We continue to invest robustly for the future, maintaining our focus on innovation, service and achieving optimal health outcomes. We are confident that these investments will create value for plan sponsors and patients and will continue to drive growth in shareholder value.”